Cargando…
A case of multi-agent drug resistant choriocarcinoma treated with Pembrolizumab
• High-risk multi-agent drug resistant GTN is a life threatening disease. • Majority of choriocarcinomas show intense PD-L1 immunoreactivity. • Pembrolizumab increases antitumor activity. • Effectiveness of Pembrolizumab in treating patients with high-risk multi-agent drug resistant GTN.
Autores principales: | Goldfarb, Jennifer A., Dinoi, Giorgia, Mariani, Andrea, Langstraat, Carrie L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210394/ https://www.ncbi.nlm.nih.gov/pubmed/32395603 http://dx.doi.org/10.1016/j.gore.2020.100574 |
Ejemplares similares
-
Non-gestational choriocarcinoma with hyperprogression on pembrolizumab: A case report and review of the literature
por: Kazemi, Nazanin Yeganeh, et al.
Publicado: (2022) -
Combined chemotherapy and pembrolizumab salvages multi-chemotherapy agent and avelumab resistant choriocarcinoma: A case report
por: Lehmann, M., et al.
Publicado: (2023) -
Pembrolizumab for treatment of a male with primary mediastinal choriocarcinoma: a case report
por: Pan, Weiyu, et al.
Publicado: (2022) -
Long-term survival in multiresistant metastatic choriocarcinoma after pembrolizumab treatment: A case report
por: Paspalj, V., et al.
Publicado: (2021) -
Successful treatment of metastatic refractory gestational choriocarcinoma with pembrolizumab: A case for immune checkpoint salvage therapy in trophoblastic tumors
por: Clair, Kiran H., et al.
Publicado: (2020)